Get the Stockscreener App
25.32
3.20%
0.765
Pulse Biosciences Inc stock is traded at $25.32, with a volume of 220.18K.
It is up +3.20% in the last 24 hours and up +8.27% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$24.55
Open:
$25
24h Volume:
220.18K
Relative Volume:
0.68
Market Cap:
$1.75B
Revenue:
$751.00K
Net Income/Loss:
$-74.57M
P/E Ratio:
-22.95
EPS:
-1.1031
Net Cash Flow:
$-54.46M
1W Performance:
+32.78%
1M Performance:
+8.27%
6M Performance:
+86.56%
1Y Performance:
+47.38%
1-Day Range:
$24.60
$25.62
1-Week Range:
$20.74
$27.98
52-Week Range:
$12.56
$27.98
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.30 | 1.70B | 751.00K | -74.57M | -54.46M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
435.67 | 149.15B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.42 | 39.53B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.50 | 31.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.77 | 30.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
204.62 | 29.28B | 5.54B | 1.52B | 1.74B | 10.37 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences CEO Buys 15,000 Shares: SEC Filing Details | May 2026News and Statistics - IndexBox
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
(SEC Amendment) Pulse Biosciences(PLSE.US) 10% Shareholder Buys US$13 Million in Common Stock - Moomoo
Pulse Biosciences director Robert W. Duggan acquires $13m in stock - Investing.com India
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
Pulse Bio rises after over $13M insider buying - MSN
Pulse Biosciences stock hits 52-week high at 26.33 USD By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Q1 2026 Financial Report – Revenue, Losses, and Key Corporate Updates - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System Study - Medical Product Outsourcing
Pulse Biosciences stock hits 52-week high at 26.33 USD - Investing.com India
Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization - AD HOC NEWS
PULSE BIOSCIENCES, INC. 1Q 2026: Revenue $401K, EPS ($0.27) — 10-Q Summary - TradingView
Pulse Biosciences Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy - Stock Titan
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026Slideshow - Seeking Alpha
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing - Moomoo
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com Canada
Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus
Pulse Biosciences (PLSE) Stock Soars After Insider Buying - GuruFocus
Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - MEXC
Pulse Biosciences stock (US73242P1030): CEO buys $295K in shares - AD HOC NEWS
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - MEXC Exchange
Pulse Biosciences stock jumps after insiders buy $13.3M in shares By Investing.com - Investing.com South Africa
Pulse Bio rises after over $13M insider buying (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences insiders buy $13.3 million in stock By Investing.com - Investing.com South Africa
Pulse Biosciences insiders buy $13.3 million in stock - Investing.com
ATM equity purchases by Pulse Biosciences' co-chairmen total approximately $13.3 million - marketscreener.com
ATM Equity Purchases By Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million - TradingView
$13.3M insider stock buy: Pulse Biosciences chiefs add 675K shares - Stock Titan
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - marketscreener.com
Pulse Biosciences Insider Bought Shares Worth $295,350, According to a Recent SEC Filing - Moomoo
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million - 富途牛牛
Insider Buying: Paul Laviolette Acquires 15,000 Shares of Pulse Biosciences Inc (PLSE) - GuruFocus
Pulse Biosciences CEO Paul LaViolette acquires $295,350 in shares - Investing.com India
Pulse Biosciences CEO Paul LaViolette acquires $295,350 in shares By Investing.com - Investing.com Nigeria
Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy - Stock Titan
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):